AAV gene therapy for hereditary spastic paraplegia type 50: a phase 1 trial in a single patient.

MLA

Dowling, James J., et al. “AAV Gene Therapy for Hereditary Spastic Paraplegia Type 50: A Phase 1 Trial in a Single Patient.” Nature Medicine, vol. 30, no. 7, July 2024, pp. 1882–87. EBSCOhost, https://doi.org/10.1038/s41591-024-03078-4.

APA

Dowling, J. J., Pirovolakis, T., Devakandan, K., Stosic, A., Pidsadny, M., Nigro, E., Sahin, M., Ebrahimi-Fakhari, D., Messahel, S., Varadarajan, G., Greenberg, B. M., Chen, X., Minassian, B. A., Cohn, R., Bonnemann, C. G., & Gray, S. J. (2024). AAV gene therapy for hereditary spastic paraplegia type 50: a phase 1 trial in a single patient. Nature Medicine, 30(7), 1882–1887. https://doi.org/10.1038/s41591-024-03078-4

Chicago

Dowling, James J, Terry Pirovolakis, Keshini Devakandan, Ana Stosic, Mia Pidsadny, Elisa Nigro, Mustafa Sahin, et al. 2024. “AAV Gene Therapy for Hereditary Spastic Paraplegia Type 50: A Phase 1 Trial in a Single Patient.” Nature Medicine 30 (7): 1882–87. doi:10.1038/s41591-024-03078-4.